Background and Purpose-We sought to demonstrate that tumor necrosis factor (TNF)-␣, via sphingosine-1-phosphate signaling, has the potential to alter cochlear blood flow and thus, cause ischemic hearing loss. Methods-We performed intravital fluorescence microscopy to measure blood flow and capillary diameter in anesthetized guinea pigs. To measure capillary diameter ex vivo, capillary beds from the gerbil spiral ligament were isolated from the cochlear lateral wall and maintained in an organ bath. Isolated gerbil spiral modiolar arteries, maintained and transfected in organ culture, were used to measure calcium sensitivity (calcium-tone relationship). In a clinical study, a total of 12 adult patients presenting with typical symptoms of sudden hearing loss who were not responsive or only partially responsive to prednisolone treatment were identified and selected for etanercept treatment. Etanercept (25 mg S.C.) was self-administered twice a week for 12 weeks. Results-TNF-␣ induced a proconstrictive state throughout the cochlear microvasculature, which reduced capillary diameter and cochlear blood flow in vivo. In vitro isolated preparations of the spiral modiolar artery and spiral ligament capillaries confirmed these observations. Antagonizing sphingosine-1-phosphate receptor 2 subtype signaling (by 1 mol/L JTE013) attenuated the effects of TNF-␣ in all models. TNF-␣ activated sphingosine kinase 1 (Sk1) and induced its translocation to the smooth muscle cell membrane. Expression of a dominant-negative Sk1 mutant (Sk1
and reductions in cochlear blood flow [3] [4] [5] can induce hearing loss, a condition that affects Ϸ36 million Americans. 6 Most investigations have separated the 2 etiologic factors (that is, inflammation versus vasculopathy), under the assumption that the 2 pathogenic mechanisms are distinct and mutually exclusive. Recent experimental [7] [8] [9] and clinical 10 -12 data demonstrate that tumor necrosis factor (TNF)-␣ sequestration significantly improved auditory function in a large subgroup of idiopathic hearing loss patients: the beneficial clinical outcomes have been widely interpreted as supporting evidence that idiopathic hearing loss is primarily caused by direct inflammatory damage to cochlear cells. The present investigation, however, presents an alternative scenario: because TNF-␣ has the capability to alter vascular reactivity, 13 loss of hearing could arise from a vascular response that compromises the energy-intensive process of hearing transduction (that is, cochlear ischemia). 14 Cochlear blood flow relies exclusively on the spiral modiolar artery (SMA), a functional end-artery (that is, lacking collaterals). 15 The fine spatial distribution of blood flow is controlled by the cochlear microvascular networks, which ultimately feed the stria vascularis. This architecture creates a direct relationship between the location of flow restriction and the extent of auditory symptoms (that is, range of frequencies affected). Thus, more proximal flow restrictions are prone to yield widespread auditory symptoms (pantonal hearing loss), whereas the symptoms resulting from distal flow restrictions would be more discrete (hearing loss in a narrow frequency range). Despite the vital function of cochlear blood flow, remarkably little is known about the molecular mechanisms that regulate cochlear microvascular tone or its potential connection to hearing loss. We have previously described that tone 16 and resistance to blood flow 15 in the SMA are principally controlled by the proconstrictive phospholipid, sphingosine-1-phosphate (S1P). The S1P-generating enzyme sphingosine kinase 1 (Sk1) is activated by TNF-␣, 17 which, in principle, imbues this cytokine with the potential to profoundly disturb the cochlear microcirculation.
The present study proposes that inflammation, via TNF-␣-dependent activation of S1P signaling, can reduce cochlear blood flow. To advance this vascular hypothesis, we assessed the effect of TNF-␣/S1P signaling on cochlear blood flow/arteriolar tone (intravital microscopy of the cochlear microvascular) and capillary diameter (ex vivo spiral ligament preparation). To provide evidence for a vascularly based mechanism in humans, the recovery profiles of a selected, small group of etanercepttreated hearing loss patients were compared with those of kinetics predicted for a primary vascular origin.
Methods

Animal Models
This investigation conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) . All experimental protocols complied with Canadian, American, and German federal animal protection laws and were approved by the respective institutional animal care and use committees.
Intravital fluorescence microscopy to measure blood flow and capillary diameter in the stria vascularis was accomplished via intravenous injection of fluorescein isothiocyanate-labeled dextran into anesthetized guinea pigs in combination with standard intravital fluorescence microscopy techniques. 18 To measure capillary diameter ex vivo, capillary beds from the gerbil spiral ligament were isolated from the cochlear lateral wall and maintained in an organ bath. 19 Because direct measurement of capillary diameter yields a poor signal-to-noise ratio, an indirect method based on the measurement of red blood cell (RBC) movement with the capillary lumen was used. 19, 20 The gerbil SMA was isolated from the modiolus, cut into Ϸ1.5-mm segments, cannulated, and hydrostatically pressurized (30 cmH 2 O) 15, 21 ; vessels were then cultured for 24 hours before experimentation. Genetic constructs (Sk1 G82D , Sk1 S225A , and Sk1-green fluorescent protein [GFP] ) were transfected during the culture period. All values of tone represent acute diameter measurements that were normalized, so the values represent the magnitude of vessel constriction relative to maximal diameter. Variability in baseline calcium sensitivity prevents the direct statistical comparison of data from separate experimental series (described in the online-only Data Supplement). Sk1-GFP was visualized in SMA smooth muscle cells under live conditions with a Zeiss LSM410 confocal microscope equipped with a krypton/argon laser and a 63ϫ/1.2W waterimmersion objective.
Assessment of Auditory Function in Etanercept-Treated Patients
The use of human subjects in this study was approved by the human studies ethics committee of the Technische Universität München, Munich, Germany (No. 2172/08). A detailed description of the selection/exclusion criteria, prestudy assessments, and a patient composite is located in the online-only Data Supplement. A total of 12 adult patients presenting with the typical symptoms of sudden hearing loss who were unresponsive or only partially responsive to prednisolone treatment were identified and selected for etanercept treatment. Etanercept (25 mg S.C.) was self-administered twice a week for 12 weeks.
Hearing function was assessed by pure-tone audiometry, speech reception threshold, and word recognition. A pure-tone-average investigation was performed at 9 frequencies between 250 and 6000 Hz. Hearing improvement was defined as an improvement of (1) hearing from baseline, (2) Ն20 dB in the pure-tone air-conduction thresholds in at least 3 of the tested frequencies, and (3) 15 dB at 2 consecutive frequencies.
Statistics
Data represent meanϮSEM for n experiments. Experimental groups were compared by paired or unpaired Student's t tests, or ANOVA followed by a t test with a Bonferroni correction for multiple comparisons, as appropriate. Differences were considered significant at PϽ0.05.
Results
TNF-␣ superfusion (1 ng/mL, 20 minutes) rapidly reduced guinea pig cochlear blood flow (determined as RBC velocity) from 132.9Ϯ4.0 to 86.8Ϯ6.0 m/s, with a half-maximal effect reached after 7 minutes ( Figure 1B ). S1P 2 receptor blockade (10 mol/L JTE013; 10-minute superfusion before addition of TNF-␣) fully prevented this response ( Figure 1B) . The TNF-␣-stimulated reduction in cochlear blood flow was associated with a decrease in capillary diameter (from 9.0Ϯ0.4 to 6.7Ϯ0.2 m), which was also prevented by S1P 2 receptor blockade ( Figure 1C ). Systemic effects of the treatments can be excluded, because arterial pressure remained constant throughout the experiment (data not shown).
Consistent with Figure 1C , TNF-␣ constricted gerbil spiral ligament capillaries ex vivo (lengthϭ260Ϯ23 m; diameterϭ7.2Ϯ0.2 m) in an S1P 2 receptor-dependent manner (that is, inhibition by 10 mol/L JTE013; Figure 2B ). Accordingly, S1P also stimulated capillary constriction ( Figure 2C and supplemental Figure I ) with an estimated median effective concentration of 4.7 mol/L (supplemental Figure II) .
In the isolated gerbil SMA, a model with the unique advantage in that it can be transfected, TNF-␣ (1 ng/mL, 2 hours) significantly increased vasoconstriction in response to calcium under depolarizing conditions (plateau of maximal tone; T max conϭ26Ϯ1; TNF-␣ϭ41Ϯ4% of maximal diameter, nϭ5; Figure 3A ). TNF-␣ had no effect on resting SMA tone. Etanercept (a competitive TNF-␣ inhibitor) cotreatment prevented the TNF-␣-mediated increase in SMA tone (T max conϭ21Ϯ1; TNF-␣ϩetanerceptϭ19Ϯ1% of maximal diameter, nϭ5; Figure 3B ). JTE013 (1 mol/L, 30 minutes) also fully reversed the effect of TNFϭ␣ (T max conϭ37Ϯ5, TNFϭ␣ϭ50Ϯ5, TNF-␣ϩJTE013ϭ33Ϯ4% of maximal diameter; Figure 4A) ; however, unlike etanercept ( Figure 3B ), JTE013 significantly decreased basal calcium sensitivity (T max conϭ23Ϯ3, JTE013ϭ11Ϯ2% of maximal diameter; Figure 4B ). The 1 mol/L JTE013 concentration appeared to specifically inhibit S1P responses (online-only supplemental results). In SMAs expressing GFP-tagged Sk1 (GFP-Sk1) within their smooth muscle cells, TNF-␣ (1 ng/mL, 2 hours) stimulated TNF-␣ and S1P stimulate vasoconstriction of spiral ligament capillaries. Changes in capillary diameter (dia) were measured in an ex vivo preparation of capillary beds isolated from the spiral ligament of the cochlear lateral wall. A, Capillaries were occluded on one end and opened on the other end, and the RBCs trapped inside were visualized by laser scanning microscopy. The capillary lumen between the occluder and the RBC was assumed to be a cylinder of constant volume: vasoconstriction (assumed to be proportional to changes in diameter and length) forces the movement of RBCs toward the open end of the capillary, providing a highly sensitive measure of vasoconstriction magnitude. B, TNF-␣ (1 ng/mL) stimulated capillary vasoconstriction (open circles, nϭ7), which could be completely blocked by JTE013 pretreatment (10 mol/L; closed circles, nϭ4). C, S1P (response to 100 mol/L shown) also stimulated capillary vasoconstriction (nϭ9). *Denotes a significant difference (PϽ0.05) between the control and JTE013.
translocation of GFP-Sk1 from a primarily cytosolic location ( Figure 5A ) to the plasma membrane ( Figure 5B ). This translocation serves as a marker of Sk1 activation. 22, 23 Expression of a dominant-negative Sk1 mutant (Sk1 G82D ) in SMA smooth muscle cells, which would be expected to reduce endogenous S1P levels, virtually abolished calcium sensitivity (T max conϭ26Ϯ2, Sk1 G82D ϭ4Ϯ1% of maximal diameter; PϽ0.05) and eliminated the proconstrictive effect of TNF-␣ (T max of TNF-␣ϭ32Ϯ2, Sk1
G82D ϩTNF-␣ϭ6Ϯ2%, nϭ7; PϽ0.05 comparing Sk1
G82D ϩTNF-␣ with TNF-␣ alone; PϾ0.05 comparing Sk1 G82D with Sk1 G82D ϩTNF-␣; Figure 5C ). Because long-term inhibition of endogenous S1P synthesis potentially impacts smooth muscle cell homeostasis, 24 these experiments were complemented with a series that used a competitive chemical inhibitor, dimethylsphingosine (DMS; 3 mol/L, 30 minutes). The effects of DMS were virtually identical to those of Sk1 G82D -mediated inhibition of Sk1 ( Figure 5D ). Additionally, the application of DMS after exposure to TNF-␣ fully reversed the TNF-␣-mediated enhancement on calcium sensitivity ( Figure 5E ).
An extracellular-regulated kinase (ERK) phosphorylation site at serine 225 is critical for Sk1 activation and translocation in response to several stimuli, including TNF-␣. 23 Expression of a mutant Sk1 that cannot be phosphorylated at serine 225 (Sk1 S225A ) prevented the TNF-␣-dependent increase in calcium sensitivity ( Figure 4F ; T max of Sk1 S225A ϭ25Ϯ3, T max of Sk1 S225A ϩTNF-␣ϭ23Ϯ2%; nϭ5). Unlike SMAs expressing Sk1 G82D , SMAs expressing Sk1 S225A retained a significant level of calcium sensitivity (compare Figure 5C and 5F). In HEK293T cells, TNF-␣ signals via TNF-␣ receptor-associated factor 2 to activate Sk1. 25 In the SMA, however, expression of an Sk1 mutant lacking its TNF-␣ receptorassociated factor 2 binding motif (TB2-Sk1) failed to prevent the TNF-␣-dependent increase in calcium sensitivity (T max of TB2-Sk1ϭ22Ϯ5, T max of TB2-Sk1ϩTNF-␣ϭ29Ϯ4; nϭ6,
PϽ0.05).
To translate our rodent data into a human background, we recruited a small number of otherwise nonresponsive suddenhearing-loss patients for off-label treatment with etanercept (a TNF-␣ inhibitor). Patients were subcategorized into "acute" (symptoms present Ͻ3 months) and "chronic" (symptoms present for Ͼ3 months) hearing loss cases. Etanercept treatment improved 6 of the 7 acute hearing loss cases but only 2 of the 7 chronic hearing loss cases. The kinetics data for acute hearing loss patients who responded to treatment were perfectly fit by a 1-phase, exponential decay curve (calculated half-lifeϭ1.56Ϯ0.20 weeks, r 2 ϭ0.9916; Figure 6 ); after 12 
Discussion
Using in vivo and in vitro models, this investigation has demonstrated that TNF-␣ induces a proconstrictive state throughout the cochlear microcirculation. In accordance with our overall hypothesis, TNF-␣ caused a rapid reduction of blood flow within the guinea pig stria vascularis, which was associated with decreased capillary diameter. TNF-␣ has been shown to elicit vasoconstriction in both human mammary arteries 26 and mouse cerebral arteries 27 : our in vitro measurements in spiral ligament capillaries confirmed that the TNF-␣-stimulated reduction in capillary diameter was, in fact, an active constriction, rather than a passive collapse of the capillaries. 20, 28 It is therefore tempting to speculate that microregional TNF-␣ production could compromise blood flow in specific regions along the length of the cochlea, which could give rise to hearing loss in distinct frequency ranges. In addition to stimulating vasoconstriction within the distal cochlear microcirculation, TNF-␣ also augmented calcium sensitivity (that is, a proconstrictive state) in the more proximal gerbil SMA. Etanercept was able to block the TNF-␣-stimulated augmentation of calcium sensitivity in the SMA, which may in part explain the beneficial clinical effects of the drug in a subgroup of hearing loss patients. 10, 11 A common feature of all parameters studied in the experimental models (that is, blood flow, capillary constriction, and SMA calcium sensitivity) is the susceptibility of TNF-␣ effects to the S1P 2 antagonist JTE013. This links the effects of TNF-␣ to microvascular S1P signaling and is consistent with the known role of TNF-␣ as an activator of Sk1. 24 Indeed, we were able to visualize TNF-␣-stimulated translocation of Sk1 (an activation marker) and demonstrate that the tone- Figure 5 . TNF-␣ activates Sk1 to enhance SMA calcium sensitivity. A, Under resting conditions, GFP-Sk1 was homogenously distributed throughout the cytosol. B, TNF-␣ (1 ng/mL, 2 hours) stimulated a redistribution of GFP-Sk1 to the plasma membrane. C, Expression of a dominant-inactive Sk1 mutant dramatically reduced the resting SMA calcium sensitivity (ie, a rightward shift in the calcium/tone relation), compared with controls. TNF-␣ augmented calcium sensitivity in control SMAs but not in those expressing the dominant-negative Sk1 mutant Sk1 G82D (maximal diameter [dia max ] of controlϭ90Ϯ7 m, nϭ7; dia max of Sk1 G82D ϭ92Ϯ7 m; nϭ7). D, The effects of the chemical inhibition of Sk (by DMS, 3 mol/L, 30 minutes) were similar to that of Sk1 G82D expression: it reduced resting calcium sensitivity and prevented the calcium sensitivity increase after subsequent application of TNF-␣ (dia max ϭ87Ϯ9 m, nϭ7 paired observations). E, DMS also reversed the TNF-␣-stimulated enhancement of SMA calcium sensitivity (dia max ϭ86Ϯ4 m, nϭ5 paired observations). F, TNF-␣ failed to increase calcium sensitivity in SMAs expressing the nonphosphorylatable, but catalytically active, Sk1 mutant Sk1 S225A . *Denotes a significant difference (PϽ0.05) in the dose-response relations.
enhancing effect of TNF-␣ critically depends on a functional Sk1 enzyme ( Figure 5 ).
In addition to blocking the effects of TNF-␣, inhibition of Sk1 catalytic activity with a dominant-negative mutant (Sk1 G82D ) also profoundly reduced basal SMA calcium sensitivity; JTE013 displayed similar effects. These are important observations, because the SMA serves as a resistance artery and thus protects the cochlear microcirculation from systemic pressures. 16 The indiscriminate interruption of S1P signaling could therefore compromise this important function and lead to excessive pressure within the inner ear microcirculation: such a mechanism may explain why the S1P 2 receptor-knockout mouse is deaf as a result of structural damage to the cochlear microcirculation and strial tissue. 16 Because the SMA's resistance-artery function appears to be dependent on constitutive S1P synthesis, interventions that target the S1P 2 receptor (JTE013) and/or S1P synthesis (DMS) may not represent viable clinical strategies to counter the tone-enhancing effects of TNF-␣.
We therefore assessed the effect of a catalytically active Sk1 mutant that lacks the ERK1/2 phosphorylation motif (Sk1 S225A ) necessary for TNF-␣-stimulated activation of the enzyme. 23 Remarkably, expression of Sk1 S225A abolished the effect of TNF-␣ but retained a significant degree of calcium sensitivity. This identified the phosphorylation-dependent activation of Sk1 as a more precise molecular target for selective therapeutic approaches aiming to reduce the deleterious vascular effects of TNF-␣. The fact that ERK1/2-dependent Sk1 phosphorylation integrates several inflammatory cytokine inputs (for example, interleukins 1␤ and -6) 29, 30 highlights the additional potential of this suggested therapeutic approach as a more general means to interfere with the microvascular effects of inflammatory processes. Pitson and coworkers 25 have proposed that TNF-␣-mediated Sk1 activation requires direct multiplexing with the TNF-␣ receptor, via an interaction with TNF-␣ receptor-associated factor 2. The lack of effect of TB2-Sk1 expression in the SMA, however, suggests that the TNF-␣-mediated increase in calcium sensitivity relies on ERK1/2 activation downstream of the TNF-␣ receptor.
Patients who responded to etanercept displayed a functional hearing-recovery time course that could be tightly fitted to a single exponential function possessing an average time constant of 1.5 weeks. We acknowledge that the patient group was small; however, the time course, combined with low interpatient variability, suggests a single common mechanism underlying the benefit of etanercept treatment (that is, sequestration of TNF-␣). The time course of hearing recovery, Ϸ10 to 15 days, is consistent with the combined time for etanercept to reach effective plasma levels (Ϸ2 days), 31 the normalization of blood flow (rather immediate, once therapeutically relevant concentrations of etanercept are established within the vascular wall), and for the endocochlear potential to be restored after oxygen deprivation (Ϸ7 days). 32 Although none of these individual clinical observations directly links hearing loss to reductions in cochlear blood flow, the cumulative evidence provided from the human and animal data in this investigation supports a strong vascular component in the pathogenesis of hearing loss. Although we cannot exclude direct effects of TNF-␣ on hair cells (for example, apoptosis), 33 the reversibility shown in Figure 6 is more consistent with a vascularly based mechanism.
In summary, our data indicate that TNF-␣ induces a proconstrictive state at all levels of the cochlear microcirculation via activation of S1P signaling: therefore, any pathology linked to the release of TNF-␣ (infection, autoimmune disorders, systemic inflammatory responses, etc) has the potential to cause vascularly based, ischemic hearing loss. In this scenario, failure of hearing transduction is secondary to ischemia in the inner ear, events that result from increased resistance to cochlear blood flow due to vasoconstriction of the SMA and cochlear microcirculation. As a result, this investigation integrates a subgroup of hearing loss cases into the family of ischemic vascular pathologies, with immediate implications related to risk stratification, diagnosis, and treatment. Fund 
Disclosures
None. Figure 6 . Kinetics of etanercept-mediated improvement of auditory function in hearing loss patients. Displayed is the recovery kinetics curve from 6 clinical cases of hearing loss after off-label treatment with etanercept; all patients sought treatment within 3 months of developing symptoms. In 6 of 7 ears treated (1 patient had bilateral hearing loss), etanercept improved auditory function. Of these 6 responding ears, 50% of the maximal effect was achieved after 1.5 weeks. The kinetics almost perfectly fits a 1-phase exponential decay function (r 2 ϭ0.9916). , Sk1-GFP) have been previously described 1,2 . The TB2-Sk1 construct was prepared using site-directed mutagenesis as previously and Xylazine (Rompun®; Bayer, Leverkusen, Germany) were used to anesthetize guinea pigs for intravital microscopy experiments. 
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SUPPLEMENTAL MATERIALS AND METHODS
Materials
Experimental Procedures
This investigation conforms to the Guide for the Care and Use of Laboratory Animals
Intravital fluorescence microscopy of the cochlear microcirculation
The guinea pig cochlear window preparation has been described previously 4 . Male albino
Hartley guinea pigs (250-400g) that were anesthetized with i.p. injections of Ketamine/Xylazine (initial dose of 85mg/kg / 8.5mg/kg and supplemented 42.5mg/kg / 4.25mg/kg every 45 minutes thereafter). The core body temperature of anesthetized animals was kept at 38±1°C using a thermostatically controlled heating pad. A left femoral artery polyethylene catheter (PE50) served to monitor systemic blood pressure and obtain blood sample for arterial blood gas and serum electrolyte evaluation; intravenous injections were applied through a right external jugular vein catheter. Heart rate and pulse oxygenation of the spontaneously breathing animals were continuously monitored.
The mastoid bulla was exposed and removed through a postauricular approach to the right ear.
To provide better access to the cochlea, the tympanic membrane, the posterior annulus, and the tensor tympani tendon were cut and all middle ear ossicles sacrificed. Mucosa and mucosal vessels overlying the second and the third cochlear turns were gently wiped off by a piece of gel foam. A small rectangular window (0.2 x 0.3 mm in size) was cut over the convex part of the second turn and a small intact piece of bone was removed from the cochlea. The cochlear bony wall was elevated without traumatizing the underlying spiral ligament and stria vascularis to expose blood vessels in these tissues.
Intravital microscopy was performed using a modified Zeiss microscope (Axiotech Vario; Zeiss, Goettingen, Germany) and intravenously injected fluorescein isothiocyanate (FITC)-labelled dextran (MW 500,000; 0.05-0.1 ml of a 5% solution in 9% NaCl) to visualize the cochlear microcirculation. FITC was excited by epi-illumination (100 W mercury lamp) and observed via specific fluorescence filter blocks (excitation 450-490 nm, emission 515 nm). The area of interest within the cochlear window was magnified using a long distance 20x objective (Olympus SLMPlan). Images were acquired using a SIT video camera (C2400-08; Hamamatsu, Herrsching, Germany) and digitally recorded (AY-DV124AMQ; Panasonic, NJ, USA) for subsequent off-line analysis of vessel diameter and blood flow (Cap Image analysis system; Zeintl, Heidelberg, Germany). For each treatment group (i.e., TNF and TNF+JTE013), parameters were analyzed using a total of 6 capillaries from 3 guinea pigs.
In vitro measurements of capillary diameter
The isolation of gerbil spiral ligament capillary beds has been previously described 5 diameter. The precise model relating RBC movement to diameter is well-defined and has been described in detail previously 5, 6 .
Isolated capillaries were occluded on one end, opened on the other end, and RBCs trapped inside the lumen were visualized by laser-scanning microscopy (510 Meta, Carl Zeiss, Göttingen, Germany). The capillary lumen between the occluded end the RBC was assumed to be a cylinder of constant volume that undergoes proportional changes in diameter and length during vasoconstriction. The length of the capillary was determined using a hyperosmotic step 
In vitro measurements of vascular tone in the spiral modiolar artery
The isolation of the spiral modiolar artery (SMA) has been previously described in detail 7,8 .
Gerbils were euthanized and then decapitated. The temporal bones were removed from the head, opened and placed in micro-dissection chamber containing ice-cold MOPS buffer. The otic capsule enclosing the cochlea was opened and the bone surrounding the modiolus was removed.
The SMA was then gently removed from the eighth cranial nerve, taking care not to stretch the artery. Once isolated, the SMA was cut into ~1.5mm segments, cannulated and pressured hydrostatically to 30cmH 2 O. The vessel segments were maintained in culture medium for 24 hours, with continuous perfusion (culture medium) at a rate of 0.5ml/h. Transfection of genetic constructs (Sk1 G82D , Sk1
S225A
, Sk1-GFP) 1,2 was completed during the 24 hour vessel culture period using Effectene® reagent (Qiagen; Hilden, Germany), according to the manufacturer's instructions.
All functional experiments were performed at 37 o C in MOPS buffer, as previously described 8 . We have observed that the baseline level of calcium sensitivity can significantly fluctuate in separate batches of animals. We cannot explain why this occurs, however, the animal-to-animal variability within a batch of animals is generally quite consistent, which allows for clear statistical results with only 5-6 experiments per group. All experiments were therefore designed as paired experiments (i.e., pre/post-treatment) or, in the case of transfection experiments, all treatment groups within an experimental series were completed with the same batch of animals.
Statistical comparisons across different experimental series were avoided.
Description of human subjects included in etanercept treatment study
The use of human subjects in this study conforms with the principles outlined in the Declaration A composite of the patients included in the study is provided in Supplemental Table 1 . A total of 19 ears (from 12 patients) with hearing loss were monitored; these were subcategorized into 9 cases of "acute" (symptoms <3 months) and 10 cases of "chronic" (symptoms present for >3 months) hearing loss, depending on when treatment for the condition was sought. Two 
SUPPLEMENTAL RESULTS
Specificity of JTE013
We have previously demonstrated that JTE013 inhibits S1P-stimulated vasoconstriction in the SMA and hamster resistance arteries 10 . However, demonstrating that JTE013 specifically inhibits S1P 2 receptor-dependent responses in the SMA is rather difficult, because only two agents have been documented to evoke vasoconstriction in un-branched SMA segments (which we use in our experimental setup) to date: endothelin-1 (ET-1) and S1P. Although ET-1 stimulates SMA vasoconstriction, a portion of the response appears to be dependent on S1P
(i.e., ET-1 stimulates S1P synthesis and consequently S1P 2 receptor dependent signaling pathways; unpublished observations): thus, ET-1 responses in the SMA could be partially inhibited by JTE013. In support of these observations, ET-1-dependent activation of Sk1 in smooth muscle cells has been demonstrated previously by others 11 .
As an alternate means of assessing JTE013 specificity, we assessed the effect of JTE013 on norepinephrine responses in isolated hamster gracilis muscle resistance arteries 12 . We used a norepinephrine concentration of 0.3μM, which elicits a sub-maximal constriction of the hamster resistance artery. We found no effect of JTE013 (pre-JTE013: 37±3%; post-JTE013: 38±2%; n=6 paired observations, P>0.05). We acknowledge that this control experiment was conducted using a different species and a vessel from a different vascular bed; however, in conjunction with our previous evidence that JTE013 inhibits S1P-dependent vasoconstriction in the same artery Table 1 .
Demographic characteristics of patients treated with etanercept
Patients had a mean age of 44.4 ± 4.6 years. Involvement describes if patients had one or both ears affected. Acute hearing loss (AHL) was defined as a hearing loss that happened less than 3 months prior to enrolment. Otherwise hearing loss was termed chronic (CHL). Cochleovestibular disease was assumed in patients that had objectifiable signs of vestibular affection in addition to hearing loss. 
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